Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Challenging’ Times For Sandoz As COVID Bites

Sales And Core Operating Profit See Double-Digit Declines Despite Biopharma Growth

Executive Summary

Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.

You may also be interested in...



Consolidation And COVID See Industry Top 10 Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, the leaders of the pack in the Generics Bulletin Top 50 have once again seen significant changes in 2021.

Sandoz Champions Stability As It Returns To Growth In Q2

Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.

Sandoz H2 Launch Ramp-Up Begins With A US First

Sandoz has kicked off what promises to be a busy second half of 2021 in terms of launches for the Novartis subsidiary, introducing the first US generic of the Feraheme feumoxytol injectable treatment for iron deficiency anemia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel